(Q55055431)

16 June 2018

title

Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization. (English)

1 reference

16 June 2018

1 reference

8

1 reference

16 June 2018

author name string

Chin-Chuan Hung

1

1 reference

16 June 2018

Wei-Lun Chang

2

1 reference

16 June 2018

Jia-Ling Ho

3

1 reference

16 June 2018

John Jen Tai

4

1 reference

16 June 2018

Tsung-Jen Hsieh

5

1 reference

16 June 2018

Hsiao-Ching Huang

6

1 reference

16 June 2018

Yow-Wen Hsieh

7

1 reference

16 June 2018

publication date

21 December 2011

1 reference

16 June 2018

published in

Pharmacogenomics

1 reference

16 June 2018

volume

13

1 reference

16 June 2018

issue

2

1 reference

16 June 2018

page(s)

159-169

1 reference

16 June 2018

Established antiepileptic drugs

cites work

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

Effectiveness of first antiepileptic drug.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

Non-synonymous single nucleotide alterations in the microsomal epoxide hydrolase gene and their functional effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

N-glucuronidation of carbamazepine in human tissues is mediated by UGT2B7.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

Sequence Variability and Candidate Gene Analysis in Two Cancer Patients with Complex Clinical Outcomes During Morphine Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

Several major antiepileptic drugs are substrates for human P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

Interaction of antiepileptic drugs with human P-glycoprotein in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

Association of MDR1 (C3435T) polymorphism and resistance to carbamazepine in epileptic patients from Turkey

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

ABC transporters and the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 -24C>T polymorphism in young and adult patients with epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

Update on pharmacogenetics in epilepsy: a brief review.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

The relationship between the pharmacology of antiepileptic drugs and human gene variation: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

Partial and generalized epilepsy with febrile seizures plus and a novel SCN1A mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

Association between SCN1A polymorphism and carbamazepine-resistant epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

Differential role of sodium channels SCN1A and SCN2A gene polymorphisms with epilepsy and multiple drug resistance in the north Indian population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

Genetic variants in microsomal epoxide hydrolase influence carbamazepine dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

UDP-glucuronosyltransferase 2B7 C802T (His268Tyr) polymorphism in bladder cancer cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

Association study of candidate genes for the prevalence and progression of knee osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

A functional polymorphism in the SCN1A gene is not associated with carbamazepine dosages in Austrian patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

Nova2 interacts with a cis-acting polymorphism to influence the proportions of drug-responsive splice variants of SCN1A.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

The clinical impact of pharmacogenetics on the treatment of epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

Predicting response to lithium in mood disorders: role of genetic polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

Clinical response to morphine in cancer patients and genetic variation in candidate genes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

Factors influencing cyclosporine blood concentration-dose ratio

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

Statistical design and analysis of pharmacogenetic trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.141

21 January 2018

Identifiers

DOI

10.2217/PGS.11.141

1 reference

16 June 2018

1 reference

16 June 2018